Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Mazdutide

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Innovent · Phase 2 · Completed · Enrollment 179

NCT06124807

Y axis: Change in body weight from baseline, %

1009080706050403020100048121620243610 mg Mazdutide, week 32, 96.1%16 mg Mazdutide, week 32, 92.23%Placebo, week 32, 23.97%3/6 mg Mazdutide, week 32, 67.64%

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • 10 mg Mazdutide, one timepoint
  • 16 mg Mazdutide, one timepoint
  • Placebo, one timepoint
  • 3/6 mg Mazdutide, one timepoint
  • 10 mg Mazdutide: week 32 96.1%
  • 16 mg Mazdutide: week 32 92.23%
  • Placebo: week 32 23.97%
  • 3/6 mg Mazdutide: week 32 67.64%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.